We use cookies to help provide you with the best possible online experience. Learn more

Press releases

Germany’s Heidelberg University Hospital will become the world’s first cancer center to use RayStation for helium ion therapy planning

PDF

RaySearch Laboratories AB (publ) and Heidelberg University Hospital’s Ion Beam Therapy Center announce the world’s first clinical release with support for helium ion therapy in treatment planning system RayStation®*.

RayStation is the first commercial treatment planning system in the world to support helium ion therapy. Heidelberg University Hospital’s Ion Beam Therapy Center will become the first in Europe with helium, and first in the world with pencil-beam scanning (PBS) delivery. 

The leading oncology center in Heidelberg, Germany, bought licenses from RaySearch for helium PBS in March 2018 and intends to conduct a clinical study of 20-50 patients starting 2021 to demonstrate the effectiveness of helium ion therapy on cancer patients.

RayStation offers support for robust optimization and evaluation, dose tracking and everything else that is already supported for proton and carbon ion therapy. Physical dose calculation is performed using a pencil beam dose algorithm implemented on the graphic processing unit, and the relative biological effective dose is determined using either the local effect model or microdosimetric kinetics model.

Prof. Dr. Dr. Juergen Debus, chairman of the department of radiation oncology at Heidelberg and director of the national center of tumor diseases, says: “It will now be possible to integrate helium treatment planning into our precision radiotherapy program including modern photon and particle beams on the RayStation platform and seamlessly optimize the treatment for every patient.” 

Johan Löf, founder and CEO, RaySearch, says: “Heidelberg has been an important clinical partner for RaySearch for several years, and it’s exciting to enter clinic trials for helium ion therapy with the esteemed team in Germany. Collaboration on this level is the drive force of innovation within precision health care and a cornerstone of our approach to innovation.”

About Heidelberg University Hospital
Heidelberg University is the oldest university in Germany; its first medical lectures were held here in 1388. Today, it is one of the largest and most prestigious medical centers in Europe, with a reputation based on excellent patient care, research and teaching. Heidelberg University Hospital offers inpatients and outpatients an innovative and effective diagnosis and therapy for all complex diseases. In modern buildings with state-of-the-art equipment specialized teams of physicians, technicians, engineers and physicists deliver medical care to the highest international standards. The proximity and interlinking of the specialist departments benefit the patient, with interdisciplinary cooperation ensuring optimal treatment.

About RaySearch
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets worldwide its treatment planning system RayStation and next-generation oncology information system RayCare. Over 2,600 clinics in more than 65 countries use RaySearch software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.

About RayStation
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare, the next-generation oncology information system. By harmonizing the treatment planning, we enable better care for cancer patients worldwide. 

* Subject to regulatory clearance in some markets.

More information about RaySearch is available at www.raysearchlabs.com

For further information, please contact:
Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com

Peter Thysell, CFO, RaySearch Laboratories AB (publ) 
Telephone: +46 (0)70 661 05 59
peter.thysell@raysearchlabs.com

PDF